- Preventative
health care market expected to see 15 percent CAGR in build toward $196.9
billion in revenues by 2024
- PreveCeutical
Medical conducting five R&D programs that aim to boost preventative
health for cancers, head injuries
- Recent
investor update highlights company’s cannabis product development efforts,
including sleep aid product agreement with Asterion Cannabis Inc.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:
18H) recently published an investor update detailing its corporate
activities (http://ibn.fm/37FYr),
particularly as they relate to its efforts to improve public health through a
novel delivery method for cannabis-related products. The report notes
PreveCeutical’s successes, underscored by its completion of a $6.5 million
financing to inject new capital into its research efforts, as well as general
capital purposes.
PreveCeutical CEO and President Stephen Van Deventer has a
long history of building up cutting edge companies, including Aurora Cannabis
Inc., together with PreveCeutical co-founder Kimberly Van Deventer. Since 2015,
PreveCeutical’s mission has been one of developing preventive therapies for
health-conscious consumers who want nature-based products.
In recent months, the company has advanced the testing of
its Nature Identical™ peptides toward the treatment and prevention of cancers such
as the glioblastoma, the disease that took the life of Sen. John McCain. The
company’s research team identified eight peptide candidates for the anticipated
line of wellness products earlier this year, building on analysis of the
Caribbean blue scorpion whose venom is widely reputed to have had a historical
benefit among islanders of treating and staving off cancers.
Under the second phase of development, PreveCeutical’s
researchers are working to redesign the eight venom peptides to improve their
stability and usefulness in drug applications (http://ibn.fm/aDmsx). Once that
work is completed, the company will begin screening the peptides in cell-based
cancer models.
PreveCeutical has been simultaneously developing its Sol-gel
formulation as a nasal gel that will deliver cannabinoid solutions in a
rapid-pass mechanism from the nose to the brain, avoiding the destructive
aspects of the digestive system that seek to vet and eliminate chemicals that
are foreign to the body.
By using Sol-gels to deliver cannabis derivatives in a
non-smoked method, PreveCeutical expects to engineer better ways of responding
to pain, inflammation, anxiety, seizures and other neurological disorders that
cannabis has a history of alleviating. The company is currently testing several
custom applicators to facilitate safe and consistent delivery of the
cannabinoids to the central nervous system in defined measurements, all with
the intent of creating a way to present medications directly where they will do
the most good with the fewest side effects.
To further its cannabis research, PreveCeutical created an
Australian subsidiary, through which the company conducts its development
projects in conjunction with the Pharmacy Australia Centre of Excellence at the
University of Queensland. PreveCeutical secured the licenses to have cannabis
shipped from Canadian cultivators to the university earlier this year.
In mid-August, 2018, privately held Asterion Cannabis Inc.,
where Van Deventer also serves as CEO and board chairman, announced that it had
granted PreveCeutical a worldwide license to use, manufacture, distribute and
sell three natural health sleep aid products that are Health Canada-approved.
The news followed on Asterion’s July announcement that it will build the
world’s largest automated greenhouse in Queensland, using renewable energy to
power the 4.3 million-square-foot facility (approximately 99 acres, or 40
hectares) for cannabis extraction, processing and research and development.
The company intends to begin manufacturing the Natural
Health Products line of sleep aids and sell them in retail pharmacies and
health-focused stores, as well as on PreveCeutical’s website.
PreveCeutical also has R&D programs targeting dual gene
therapy for type 2 diabetes and obesity, non-addictive analgesic peptides
as a replacement to highly addictive analgesics and a therapeutic product for
treating athletes who suffer from concussions. Through these initiatives, the
health sciences company aims to become a leader in preventative health
sciences.
Crystal Equity Research noted that the company’s successful
efforts to raise new funding in June for useable capital (http://ibn.fm/DK4Vl) put
PreveCeutical’s potential “into a higher gear with its development pipeline,”
predicting that preventative health care will remain lucrative as it builds
toward an anticipated $196.9 billion in revenue by 2024 with a 15 percent CAGR.
Grandview Research found that 60 percent of the world’s population uses some
type of medicine, whether traditional or non-conventional. The National Center
for Disease Control reported that 20 percent of the United States’ population
uses alternative therapies (http://ibn.fm/U3PIP).
For more information, visit the company’s website at www.PreveCeutical.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment